Daniela Cino

Daniela Cino

Auto-generated profile, based on publicly available information

Daniela Cino

Division of Dermatology, Department of Medicine, University of Ottawa, ON, Canada

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 November 2021 in Clinical and Experimental Dermatology
Verified
Journal Article
Closed access
PDF file
DCD. Cino
D. Cino
CDC. Drumm
C. Drumm
KSK. Sheahan
K. Sheahan
CDC. D'Arcy
C. D'Arcy
NNN. Nolan
N. Nolan
BMB. Moriarty
B. Moriarty

20 June 2025 in Sage Open Medical Case Reports
Verified
Journal Article
Open access
DCDaniela Cino
Daniela Cino
BMBarbara Marzario
Barbara Marzario
SCSophia Colantonio
Sophia Colantonio
MKMark G. Kirchhof
Mark G. Kirchhof
We report two cases of cocaine-associated dermatoses: pyoderma gangrenosum and linear IgA bullous dermatosis. These cases highlight the importance of considering less common associations with drug use in the development of certain dermatoses. Eliciting a good history around the onset of the skin condition and potential triggers is vital in establishing a causal link. In both of our cases, the lesions improved with cocaine avoidance and disease-specific treatment. Use of cocaine is most commonly associated with vasculitis, but has been reported to trigger neutrophilic dermatoses and vesiculobullous diseases. Dermatologists need to be aware of these less common cocaine-associated dermatoses, particularly when patients are not responding to standard therapy alone.

24 May 2025 in Sage Open Medical Case Reports
Verified
Journal Article
Open access
BMBarbara Marzario
Barbara Marzario
DCDaniela Cino
Daniela Cino
SCSophia Colantonio
Sophia Colantonio
This case report describes, to our knowledge, the first known successful treatment of airborne allergic contact dermatitis to sesquiterpene lactone with upadacitinib in an adult patient. Recurrent summertime photodistributed eczematous eruptions should raise suspicion for airborne allergic contact dermatitis to sesquiterpene lactone, and positive patch test results to sesquiterpene lactone and Compositae in these patients should be considered highly relevant. In addition to allergen avoidance, treatment with systemic Janus kinase inhibitors can induce allergic contact dermatitis remission. Our patient did not respond to allergen avoidance or topical corticosteroids; however, he achieved almost complete resolution of his allergic contact dermatitis with a 6-week course of upadacitinib, a Janus kinase 1 inhibitor.